<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654953</url>
  </required_header>
  <id_info>
    <org_study_id>P50DA018197</org_study_id>
    <secondary_id>P50DA018197</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00654953</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans</brief_title>
  <official_title>Sertraline Augmented With GABA Agents for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the clinical efficacy of sertraline (200 mg/day) alone or sertraline in
      combination with gabapentin. The purpose of this study is to examine whether the
      antidepressant sertraline alone or combined with gabapentin delays time to relapse relative
      to placebo in recently abstinent cocaine-dependent volunteers who are also depressed. In
      addition, whether depressive symptoms or genetic factors influence treatment response to the
      study medications will be examined. Our hypothesis is that those on combined
      sertraline-gabapentin will show a longer period of abstinence than those on sertraline alone
      or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled in this 12-wk, double blind, randomized, placebo-controlled, clinical trial
      are admitted to a residential facility in North Little Rock (RCA-NLR) and randomized by
      depressive symptom severity to receive one of the following: sertraline alone (200 mg/day),
      sertraline (200 mg/day) plus gabapentin (1200 mg/day), or placebo. Subjects are expected to
      participate in the Substance Abuse Day Treatment Program while residing on the RCA-NLR and
      being inducted onto the maintenance dose of study medication (weeks 1-2). When participants
      transfer to the Outpatient Treatment Research Unit (TRU) at the start of their third week,
      they will continue to receive study medications or placebo (weeks 3-12) and they will be
      expected to participate in weekly individual cognitive behavioral therapy. Supervised urines
      and vital signs will be obtained thrice weekly; self-reported adverse effects, mood and drug
      use self-reports will be obtained once weekly. At the end of 12 weeks, participants will be
      tapered off the study medication over a five-day period, discharged from the study, and
      referred to an appropriate treatment or treatment/research program in the community if they
      are interested.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Toxicology Screens for the Presence of Cocaine/Cocaine Metabolites</measure>
    <time_frame>70 days</time_frame>
    <description>Thrice-weekly urine samples were analyzed for the presence of cocaine/cocaine metabolite. Days to Relapse was defined as time to the second of two urine results consecutively positive for cocaine.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Depressive Symptoms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sertraline (200 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sertraline (200 mg/day) plus gabapentin (1,200 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline</intervention_name>
    <description>Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (cellulose or lactose) administered twice per day for 12 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gabapentin</intervention_name>
    <description>Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years old

          -  not currently enrolled in a treatment program

          -  subjects must have a history of cocaine use, with street cocaine use by history being
             a minimum of 1 gram during the preceding 3 months

          -  subjects must meet DSM-IV criteria for cocaine dependence as assessed by the substance
             abuse section of the Structured Clinical Interview for DSM-IV (SCID and SCID-SAC)

          -  subjects must have laboratory confirmation of recent cocaine use (positive urine for
             cocaine or benzoylecgonine) during the month prior to study entry

          -  subjects must score at least 15 on the Hamilton Depression Scale

          -  women of childbearing age must have a negative pregnancy test to enroll in this study
             and must agree to monthly pregnancy testing

        Exclusion Criteria:

          -  current diagnosis of other drug or alcohol physical dependence (other than cocaine or
             tobacco)

          -  ill health (e.g., major cardiovascular, renal, endocrine, hepatic disorder)

          -  history of schizophrenia, or bipolar type I disorder

          -  present or recent use of over-the-counter or prescription psychoactive drug or drug(s)
             that would be expected to have major interaction with drug to be tested

          -  medical contraindication to receiving study medications (e.g., for sertraline, use of
             monoamine oxidase inhibitor within last two weeks; significant history of seizures;
             significant history of head trauma or serious neurological disorders)

          -  current suicidality or psychosis

          -  Liver function tests (i.e., liver enzymes) greater than three times normal levels

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Oliveto, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205 7911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2008</study_first_posted>
  <results_first_submitted>March 28, 2011</results_first_submitted>
  <results_first_submitted_qc>March 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2011</results_first_posted>
  <last_update_submitted>March 28, 2011</last_update_submitted>
  <last_update_submitted_qc>March 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alison Oliveto Beaudoin</name_title>
    <organization>UAMS</organization>
  </responsible_party>
  <keyword>cocaine dependence</keyword>
  <keyword>depressive symptoms</keyword>
  <keyword>relapse</keyword>
  <keyword>sertraline</keyword>
  <keyword>gabapentin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>143 cocaine-using volunteers gave informed consent between 12/15/2005 and 4/8/2009. Consenting occurred at either the UAMS substance abuse treatment clinic, treatment research unit or center for addiction research at the UAMS Psychiatric Research Institute. Of these, 105 eligible participants were enrolled into the study proper.</recruitment_details>
      <pre_assignment_details>Of the 143 screened, 42 failed randomization/screening procedures and so were not randomized to receive study medication or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Group</title>
          <description>Placebo capsules</description>
        </group>
        <group group_id="P2">
          <title>Active Group: Sertraline Alone</title>
          <description>sertraline (200 mg/day)</description>
        </group>
        <group group_id="P3">
          <title>Active Group: Sertraline Plus Gabapentin</title>
          <description>sertraline (200 mg/day) plus gabapentin (1,200 mg/day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Group</title>
          <description>Placebo capsules</description>
        </group>
        <group group_id="B2">
          <title>Active Group: Sertraline Alone</title>
          <description>sertraline (200 mg/day)</description>
        </group>
        <group group_id="B3">
          <title>Active Group: Sertraline Plus Gabapentin</title>
          <description>sertraline (200 mg/day) plus gabapentin (1,200 mg/day)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.74" spread="6.32"/>
                    <measurement group_id="B2" value="39.78" spread="8.36"/>
                    <measurement group_id="B3" value="39.40" spread="7.81"/>
                    <measurement group_id="B4" value="39.31" spread="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urine Toxicology Screens for the Presence of Cocaine/Cocaine Metabolites</title>
        <description>Thrice-weekly urine samples were analyzed for the presence of cocaine/cocaine metabolite. Days to Relapse was defined as time to the second of two urine results consecutively positive for cocaine.</description>
        <time_frame>70 days</time_frame>
        <population>Participants who completed the two-week residential stay and had 2 urine samples consecutively positive for cocaine were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Sertraline</title>
          </group>
          <group group_id="O3">
            <title>Sertraline Plus Gabapentin</title>
          </group>
        </group_list>
        <measure>
          <title>Urine Toxicology Screens for the Presence of Cocaine/Cocaine Metabolites</title>
          <description>Thrice-weekly urine samples were analyzed for the presence of cocaine/cocaine metabolite. Days to Relapse was defined as time to the second of two urine results consecutively positive for cocaine.</description>
          <population>Participants who completed the two-week residential stay and had 2 urine samples consecutively positive for cocaine were included in the analysis.</population>
          <units>Days to relapse (two consec coc+ urines)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>urine samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.93" spread="12.16"/>
                    <measurement group_id="O2" value="23.38" spread="17.82"/>
                    <measurement group_id="O3" value="17.27" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis tested the null hypothesis of no difference among groups in terms of the # of days to relapse (first two conseqcutively positive urines) using ANOVA.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
            <method_desc>degrees of freedom for medication group = 2 (group)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Group</title>
          <description>Placebo capsules</description>
        </group>
        <group group_id="E2">
          <title>Active Group: Sertraline Alone</title>
          <description>sertraline (200 mg/day)</description>
        </group>
        <group group_id="E3">
          <title>Active Group: Sertraline Plus Gabapentin</title>
          <description>sertraline (200 mg/day) plus gabapentin (1,200 mg/day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <description>Allergic reaction to study medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <description>self-reported dizziness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>High Blood Pressure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and/or Emesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Chest pain in which cardiac involvement was ruled out.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>toothache and/or tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>sexual dysfunction</sub_title>
                <description>erectile dysfunction/impotence/inability or delayed orgasm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Oliveto, Ph.D.</name_or_title>
      <organization>UAMS</organization>
      <phone>501-526-8441</phone>
      <email>olivetoalison@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

